Evozyne, LLC
Funding rounds
3 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Sep 2023 | $81 M | No. 3 | $50 to $250 million | equity, debt | SEC | |
| Apr 2021 | $54 M | No. 2 | $50 to $250 million | equity | SEC | |
| Apr 2020 | $9 M | No. 1 | $2 to $10 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Evozyne, LLC chose not to state its revenue in its newest notice of a funding round (Sep 2023).
SEC Form D · Sep 2023
The industry group it chose in its notices: Biotechnology.
SEC Form D · Sep 2023
That is all the official record says: Evozyne, LLC has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
No investor of Evozyne, LLC is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 29 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Aleina M. Lee | Corporate Controller | Sep 2023 |
| Aris J. Theologis | Chief Business Officer | Sep 2023 |
| Arjun S. Rallapalli | Chief Operating Officer | Sep 2023 |
| Darien S. Parhad | Chief Financial Officer and Treasurer | Sep 2023 |
| Jeffrey S. Aronin | Chairman and Director | Sep 2023 |
| Jude M. Sullivan | General Counsel and Secretary | Sep 2023 |
| Mike S. Gamson | President, Chief Executive Officer, and Director | Sep 2023 |
| Patrick J. Morris | Executive Vice President, Legal Affairs, Assistant Secretary, and Director | Sep 2023 |
| Rama J. Ranganathan | Chief Scientific Officer and Director | Sep 2023 |
| Aris J Theologis | Manager and Chief Business Officer | May 2020 |
| Darien J Parhad | Treasurer | May 2020 |
| Patrick J Morris | Manager, Interim Chief Executive Officer, Interim President, Executive Vice President, Legal Affairs and General Counsel | May 2020 |
| Rama J Ranganathan | Manager and Chief Scientific Officer | May 2020 |
| Antonio S. Gracias | Director | Sep 2023 |
| Jeffrey S. Aronin | Chairman and Director | Sep 2023 |
| Matthew M. Rizzo | Director | Sep 2023 |
| Mike S. Gamson | President, Chief Executive Officer, and Director | Sep 2023 |
| Patrick J. Morris | Executive Vice President, Legal Affairs, Assistant Secretary, and Director | Sep 2023 |
| Rama J. Ranganathan | Chief Scientific Officer and Director | Sep 2023 |
| Aris J. Theologis | Director | Apr 2021 |
| Antonio J Gracias | Manager | May 2020 |
| Aris J Theologis | Manager and Chief Business Officer | May 2020 |
| Patrick J Morris | Manager, Interim Chief Executive Officer, Interim President, Executive Vice President, Legal Affairs and General Counsel | May 2020 |
| Rama J Ranganathan | Manager and Chief Scientific Officer | May 2020 |